Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
KORU Medical Systems Q3 2025 Earnings Call - Accelerated 27% Revenue Growth Driven by SCIG Market Expansion and Oncology Infusion Advances
KORU Medical Systems reported a strong Q3 2025 with 27% year-over-year revenue growth, fueled primarily by a 30% surge in their core subcutaneous immunoglobulin (SCIG) business fueled by international...
- KORU delivered 27% year-over-year revenue growth in Q3 2025, hitting over $10 million for the second straight quarter.
- Core U.S. subcutaneous immunoglobulin (SCIG) business grew 30%, outpacing market growth due to international expansion and global share gains.
- International revenue surged 230%, driven by successful prefilled syringe (PFS) conversions in Europe simplifying patient and healthcare professional usage.
- +13 more takeaways
Intellicheck Q3 2025 Earnings Call - Robust 28% Revenue Growth Fueled by Banking Expansion and Product Innovation
Intellicheck reported a strong third quarter for 2025, delivering revenue growth of 28% year-over-year to $6 million and achieving a new adjusted EBITDA record of $631,000. The surge was driven primar...
- Intellicheck achieved 28% revenue growth year-over-year in Q3 2025, reaching a record $6 million.
- Adjusted EBITDA hit a third-quarter record at $631,000, a significant improvement from a negative $160,000 last year.
- Primary revenue driver was a regional bank launching Intellicheck in branches, supported by a three-year contract worth high seven digits.
- +12 more takeaways
Duos Technologies Q3 2025 Earnings Call - Strategic Pivot to Edge Data Centers Drives Record Growth and Adjusted EBITDA Profitability
Duos Technologies reported a transformative third quarter, highlighted by a 112% year-over-year revenue surge to $6.88 million and achieving adjusted EBITDA profitability a quarter ahead of schedule. ...
- Duos Technologies achieved a 112% year-over-year revenue increase in Q3 2025, reaching $6.88 million, and exceeded prior profitability expectations by attaining adjusted EBITDA positive results one quarter ahead of schedule.
- The company is strategically shifting focus towards edge computing and data center power solutions, capitalizing on AI-driven demand growth and hyperscalers’ power constraints for large data centers.
- Duos holds a 5% equity stake in APR Energy and executes an asset management agreement that significantly contributes to recurring revenue, though this agreement will end in 2026, prompting diversification efforts.
- +10 more takeaways
MDxHealth Q3 2025 Earnings Call - ExoDx Acquisition Sets Stage for Sustained Growth Amid Strategic Focus Shifts
MDxHealth reported a strong Q3 2025 with revenues climbing 18% year-over-year to $27.4 million and adjusted EBITDA turning positive at $1 million, marking continued operational discipline and efficien...
- Q3 2025 revenue reached $27.4 million, up 18% from 2024, driven by strong test volumes and mix shifts.
- Adjusted EBITDA was positive $1 million in Q3, improving from negative $3.8 million the prior year, highlighting improved profitability.
- MDxHealth completed the acquisition of Exosome Diagnostics (ExoDx) at quarter-end, expanding its precision diagnostics portfolio in urology.
- +12 more takeaways
Journey Medical 3Q 2025 Earnings Call - Emrosi Launch Driving Strong Revenue Growth and Improved EBITDA
Journey Medical reported solid 3Q 2025 results, posting 21% year-over-year revenue growth led by a 75% sequential rise in Emrosi sales, their best-in-class oral treatment for inflammatory lesions of r...
- Journey Medical achieved 21% year-over-year revenue growth in 3Q 2025, driven predominantly by Emrosi's commercial success.
- Emrosi sales surged 75% sequentially from Q2 to Q3, contributing $4.9 million in revenue in the quarter.
- Total Emrosi prescriptions grew approximately 146% quarter-over-quarter, reaching 18,198 in Q3 2025.
- +12 more takeaways
MaxCyte Q3 2025 Earnings Call - Strategic SPL Growth Amid Challenging Market and Streamlined Operations
MaxCyte reported $6.8 million in Q3 2025 revenue, reflecting consistent performance despite a tough operating environment marked by prolonged ex vivo therapy funding challenges. The company signed fou...
- Q3 2025 total revenue was $6.8 million, with $6.4 million core revenue and $0.4 million SPL program-related revenue, aligning with guidance despite some timing delays.
- MaxCyte signed four new strategic SPLs in 2025, bringing total SPLs signed to 32, maintaining a strong and diversified pipeline.
- Fourteen SPL customers currently have 18 clinical programs underway; five programs anticipate pivotal studies in the next 6-18 months, targeting commercial launches in 2027-2028.
- +12 more takeaways
Immuneering Q3 2025 Earnings Call - Tevid MetNib Shows Transformational Efficacy and Tolerability in First-line Pancreatic Cancer
Immuneering's Q3 2025 earnings call spotlighted compelling clinical case studies demonstrating the potential of Tevid MetNib, in combination with FOLFIRINOX, to elicit remarkable tumor responses in fi...
- Immuneering presented two remarkable pancreatic cancer case studies with Tevid MetNib plus FOLFIRINOX, including an unconfirmed complete response and successful surgical conversion.
- Previous data showed 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with Tevid MetNib and gemcitabine nab-paclitaxel, significantly higher than the ~47% standard care benchmark.
- Tevid MetNib demonstrated a favorable tolerability profile; patients reported improved quality of life and maintained stable weight during treatment.
- +7 more takeaways
Journey Medical Q3 2025 Earnings Call - Emrosi Launch Powers 21% Revenue Surge, Approaching EBITDA Positivity
Journey Medical reported a strong third quarter in 2025 with 21% year-over-year revenue growth, largely driven by the robust commercial launch of Emrosi, their oral rosacea treatment. Emrosi prescript...
- Journey Medical achieved 21% year-over-year revenue growth in Q3 2025, primarily driven by Emrosi’s commercial launch.
- Emrosi sales reached $4.9 million in Q3, a 75% increase from Q2, with prescriptions growing approximately 146% quarter-over-quarter.
- The number of unique Emrosi prescribers rose 50% from 1,800 to over 2,700, showing rapid adoption within targeted dermatologists.
- +12 more takeaways
Celcuity Q3 2025 Earnings Call - Gedatolisib Poised as New Standard in HR+ HER2- Advanced Breast Cancer
Celcuity’s Q3 2025 earnings call spotlighted their landmark progress toward positioning gedatolisib as a new standard of care for HR positive, HER2 negative advanced breast cancer patients. The compan...
- Celcuity reported positive top-line data from the PIK3CA wild-type cohort of the phase III VIKTORIA-1 trial showing remarkable median progression-free survival (PFS) improvements: 9.3 months for the gedatolisib triplet vs. 2 months for control.
- Hazard ratios of 0.24 for the triplet and 0.33 for the doublet are unprecedented in second-line HR positive, HER2 negative advanced breast cancer, establishing new efficacy benchmarks.
- Objective response rates significantly favored gedatolisib combinations (32% triplet, 28% doublet) compared to 1% with fulvestrant alone, with median durations of response reaching 17.5 and 12 months respectively.
- +7 more takeaways
Pulmonx Q3 2025 Earnings Call - Leadership Return Amid Execution Challenges and Renewal Focus on Profitable Growth
Pulmonx’s Q3 2025 earnings call marked the return of Glenn French as CEO and Derrick Sung as COO and CFO, signaling a leadership reset aimed at addressing recent growth deceleration and operational in...
- Glenn French returned as CEO and Derrick Sung as COO/CFO to address operational challenges and accelerate value creation.
- Pulmonx reported Q3 2025 total revenue of $21.5 million, a 5% increase year-over-year, with U.S. revenue up only 1%.
- International sales grew 15% year-over-year, driven by Europe, while China saw a revenue decline.
- +12 more takeaways